Search research articles
Contact Us
Filters
Showing results (91-100 of 115) with videos related to
Page
of 12
Sort By:
Molecular Pharmacology
|
January 15, 2021
CRISPR/Cas9 Genome Editing of the Human Topoisomerase II<i>α</i> Intron 19 5' Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells
Victor A Hernandez, Jessika Carvajal-Moreno, Jonathan L Papa, et al.
Molecular Carcinogenesis
|
February 3, 2017
Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant
Ming J Poi, Junan Li, Douglas W Sborov, et al.
Antimicrobial Agents and Chemotherapy
|
October 25, 2017
Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations
April C Joice, Sihyung Yang, Abdelbasset A Farahat, et al.
Gene Expression
|
December 30, 2008
Expression of the p16INK4A/Cdkn2a gene is prevalently downregulated in human pheochromocytoma tumor specimens
Peter Muscarella, Mark Bloomston, Alexander R Brewer, et al.
Carcinogenesis
|
November 8, 2003
Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors
Junan Li, Christopher M Weghorst, Masahiro Tsutsumi, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 17, 2019
Synthesis and antileishmanial evaluation of thiazole orange analogs
Ahmed Abdelhameed, Xiaoping Liao, Craig A McElroy, et al.
Molecular Cancer Therapeutics
|
December 10, 2020
EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1
Brenna Weadick, Debasis Nayak, Avinash K Persaud, et al.
Nano Research
|
November 19, 2019
Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer
Chengxiang Zhang, Xinfu Zhang, Weiyu Zhao, et al.
Scientific Reports
|
July 11, 2015
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
Daniel H Ahn, Junan Li, Lai Wei, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
July 2, 2019
Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience
Christina M Matthews, Kristen Nymberg, Michael Berger, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 115) with videos related to
Sort By:
Page
of 12
Molecular Pharmacology
|
January 15, 2021
CRISPR/Cas9 Genome Editing of the Human Topoisomerase II<i>α</i> Intron 19 5' Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells
Victor A Hernandez, Jessika Carvajal-Moreno, Jonathan L Papa, et al.
Molecular Carcinogenesis
|
February 3, 2017
Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant
Ming J Poi, Junan Li, Douglas W Sborov, et al.
Antimicrobial Agents and Chemotherapy
|
October 25, 2017
Antileishmanial Efficacy and Pharmacokinetics of DB766-Azole Combinations
April C Joice, Sihyung Yang, Abdelbasset A Farahat, et al.
Gene Expression
|
December 30, 2008
Expression of the p16INK4A/Cdkn2a gene is prevalently downregulated in human pheochromocytoma tumor specimens
Peter Muscarella, Mark Bloomston, Alexander R Brewer, et al.
Carcinogenesis
|
November 8, 2003
Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors
Junan Li, Christopher M Weghorst, Masahiro Tsutsumi, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 17, 2019
Synthesis and antileishmanial evaluation of thiazole orange analogs
Ahmed Abdelhameed, Xiaoping Liao, Craig A McElroy, et al.
Molecular Cancer Therapeutics
|
December 10, 2020
EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1
Brenna Weadick, Debasis Nayak, Avinash K Persaud, et al.
Nano Research
|
November 19, 2019
Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer
Chengxiang Zhang, Xinfu Zhang, Weiyu Zhao, et al.
Scientific Reports
|
July 11, 2015
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
Daniel H Ahn, Junan Li, Lai Wei, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
July 2, 2019
Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience
Christina M Matthews, Kristen Nymberg, Michael Berger, et al.
Page
of 12